Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Esophageal Squamous Cell Carcinoma
Clinical trial register · China

Esophageal Squamous Cell Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Shanghai 21 Beijing 17 Hangzhou 11 Chengdu 9 Guangzhou 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University7 Second Affiliated Hospital, Zhejiang University, School of Medicine5 Shanghai Chest Hospital4 Peking University4 Shanghai Zhongshan Hospital4
Site location
Shanghai21 Beijing17 Hangzhou11 Chengdu9 Guangzhou8
All 37 locations
Target enrolment
to

Esophageal Squamous Cell Carcinoma trials in China

93 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Hebei Medical University Fourth Hospital
Phase 2
33
Shijiazhuang
2026-10
Not yet open
Hebei Medical University Fourth Hospital
Phase 2
32
Hebei
2026-09-01
Not yet open
The First Affiliated Hospital of Zhengzhou University
Observational
500
Guangzhou, Zhengzhou, Shanghai, Chengdu, Tianjin, Kunming
2026-09
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2026-08-23
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
45
Hangzhou
2026-08-17
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Changchun, Chengdu, Chongqing, Fuzhou, Ha’erbin, Jinan, Kunming, Luoyang
2026-08-13
Recruiting
Shanghai Chest Hospital
Phase 2
28
Shanghai
2026-07-30
Not yet open
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
NCT07697040Esophageal Squamous Cell Carcinoma
DrugBecotatug Vedotin
Hebei Medical University Fourth Hospital
Phase 1
12
Shijiazhuang
2026-07-01
Recruiting
Henan Cancer Hospital
Phase 3
1,044
Zhengzhou
2026-06-16
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
90
Beijing
2026-06-09
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
49
Hangzhou
2026-06-03
Not yet open
Tang-Du Hospital
Phase 2
33
Xi'an
2026-05-30
Active, closed
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
NCT07745322Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Peking University Cancer Hospital & Institute
Observational
270
Beijing
2026-05-20
Recruiting
Tang-Du Hospital
Phase 2
90
Xi'an
2026-05-05
Recruiting
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
NCT07403136Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2
104
Shanghai
2026-04-30
Recruiting
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
NCT07519486Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2
118
Chengdu
2026-04
Recruiting
Tang-Du Hospital
Phase 1/2
45
Xi'an
2026-01-28
By invitation
Peking University
Phase 2
48
Beijing
2025-11-01
Recruiting
First Affiliated Hospital Xi'an Jiaotong University
Phase 2
24
Xi'an
2025-10-30
Recruiting
QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
NCT07049185Esophageal Squamous Cell Carcinoma
DrugLenvatinib
Peking University Cancer Hospital & Institute
Phase 2
35
Beijing
2025-09-17
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Recruiting
Anhui Provincial Hospital
Phase 2
37
Hefei
2025-07-01
Not yet open
Zhigang Li
Phase 2
164
Shanghai
2025-07
Recruiting
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Hangzhou, Harbin
2025-03-27
Recruiting
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
NCT07088354Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
Tongji Hospital
Observational
300
Wuhan
2025-03-01
Recruiting
Peking University
Phase 2
35
Beijing
2024-11-01
Active, closed
West China Hospital
Phase 1
6
Chengdu
2024-10-27
Recruiting
Shanghai Zhongshan Hospital
Phase 2
100
Shantou, Shenyang, Shanghai, Tianjin, Hangzhou
2024-10-24
Recruiting
The Affiliated Hospital of Putian University
Phase 2
42
Putian
2024-09-03
Recruiting
Sun Yat-Sen University Cancer Center
Observational
50
Guangzhou
2024-08-26
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
208
Zhengzhou
2024-08-15
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
35
Hangzhou
2024-08-08
Recruiting
Zhejiang Cancer Hospital
Phase 2
92
Hangzhou
2024-08-01
Recruiting
Fujian Medical University Union Hospital
Phase 2
90
Fuzhou
2024-07-11
Not yet open
Rui-hua Xu, MD, PhD
Phase 2
70
Guangzhou
2024-07-10
Recruiting
Sichuan University
Phase 2
30
Chengdu
2024-06-30
Active, closed
Nanfang Hospital, Southern Medical University
Phase 2
30
Guangzhou
2024-06-06
Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
45
Chongqing
2024-05-07
Recruiting
Fujian Medical University Union Hospital
Phase 2
48
Fuzhou
2024-04-11
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
95
Nanjing
2024-03-31
Recruiting
Fujian Cancer Hospital
Phase 2
30
Fuzhou
2024-03-20
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
497
Beijing
2024-03-19
Recruiting
Army Medical Center of PLA
Phase 2/3
266
Chongqing
2024-03-08
Recruiting
Anhui Provincial Hospital
Observational
25
Hefei
2024-03-01
Recruiting
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 3
490
Beijing
2024-02-05
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 3
40
Nanjing
2024-02-02
Recruiting
Tongji Hospital
Phase 2
336
Wuhan
2024-01-29
Recruiting
Anhui Provincial Hospital
Not applicable
70
Hefei
2024-01-01
Active, closed
Fudan University
Not applicable
50
Shanghai
2023-12-21
Not yet open
Fudan University
Phase 2
182
Shanghai
2023-12-15
Recruiting
Shanghai Zhongshan Hospital
Phase 2
26
Shanghai
2023-12-01
Not yet open
Shanghai Chest Hospital
Phase 2
36
Shanghai
2023-12
Recruiting
AbbVie
Phase 1
325
2023-11-09
Recruiting
Zhejiang Cancer Hospital
Phase 2
31
Hangzhou
2023-10-25
Active, closed
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06165380Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
Li Zhang
Phase 2
43
Wuhan
2023-10-23
Active, closed
Shandong Boan Biotechnology Co., Ltd
Phase 3
510
Guangzhou
2023-10-12
Recruiting
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
NCT06056336Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
DrugsTislelizumab·Carboplatin
Guo Xufeng
Phase 2
73
Shanghai
2023-09-07
Active, closed
Sun Yat-sen University
Phase 1
18
Guangzhou
2023-08-31
Recruiting
Affiliated Cancer Hospital of Shantou University Medical College
Phase 1
50
Shantou
2023-08-02
Recruiting
Renmin Hospital of Wuhan University
Phase 3
155
Wuhan
2023-07-01
Recruiting
Anhui Provincial Hospital
Observational
70
Hefei
2023-07-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
NCT06173986Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer
DrugsPD-1inhibitor·Nab-paclitaxel·Cisplatin
Shanghai Chest Hospital
Phase 1/2
50
Shanghai
2023-01-10
Recruiting
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
NCT05978193Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 2
100
Shanghai
2023-01-01
Not yet open
Peking University
Phase 2
54
Beijing
2022-12-01
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT05659251Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
48
Hangzhou
2022-12-01
Active, closed
Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC
NCT05951127Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
141
Beijing
2022-11-01
Not yet open
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
NCT05244798Esophageal Squamous Cell Carcinoma
DrugSintilimab
Sichuan Cancer Hospital and Research Institute
Phase 3
420
Chengdu
2022-11-01
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Beijing, Shanghai
2022-10-25
Recruiting
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy
Fudan University
Phase 3
354
Shanghai
2022-09-27
Active, closed
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
NCT05520619Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
DrugsPaclitaxel, Cisplatin·Taxol·Tislelizumab
Sun Yat-sen University
Phase 2
114
Guangzhou
2022-09-15
Recruiting
Zhejiang Cancer Hospital
Phase 2
100
Hanzhou, Ningbo
2022-08-03
Recruiting
Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
NCT05392413Esophageal Squamous Cell Carcinoma, PD-1 Inhibitor
Nanfang Hospital, Southern Medical University
Observational
200
Guangzhou
2022-08-01
Recruiting
Henan Cancer Hospital
Phase 3
219
Zhengzhou
2022-08-01
Recruiting
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
NCT06006650Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
Tang-Du Hospital
Phase 2
114
Xi'an, Xi’an
2022-08-01
By invitation
The First Affiliated Hospital with Nanjing Medical University
Not applicable
30
Nanjing
2022-07-30
Not yet open
Shanghai Zhongshan Hospital
Not applicable
323
Shanghai
2022-07-01
Recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
NCT05252078Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases, Gastrointestinal Neoplasms
DrugsAnlotinib hydrochloride·Benmelstobart
Jiangxi Provincial Cancer Hospital
Phase 2
30
Nanchang
2022-06-02
By invitation
Qiu Guoqin
Phase 1/2
30
Hangzhou
2022-06-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 3
342
Tianjin
2021-12-01
Active, closed
Sichuan Cancer Hospital and Research Institute
Phase 2
80
Chengdu
2021-07-01
Recruiting
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
NCT05775419Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, Side Effect of Drug
The First Affiliated Hospital with Nanjing Medical University
Not applicable
1,216
Nanjing
2021-06-30
Recruiting
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT05740995Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
DrugNeoadjuvant anti-PD-1
Shanghai Zhongshan Hospital
Observational
40
Shanghai
2020-12-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
42
Hangzhou
2020-11-23
Active, closed
AstraZeneca
Phase 3
640
Anyang, Beijing, Bengbu, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2020-10-19
Active, closed
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
NCT04764227Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Radiation Therapy
DrugsPaclitaxel·Carboplatin
Fudan University
Phase 2
70
Shanghai
2020-05-30
Recruiting
Fudan University
Not applicable
320
Nanjing, Shanghai
2020-01-06
Active, closed
Fudan University
Observational
890
Shanghai
2020-01-01
Recruiting
Henan Cancer Hospital
Phase 3
456
Zhengzhou
2019-10-22
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
202
Shijiazhuang
2019-04-24
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2018-01-23
Active, closed
Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)
NCT01688908Esophageal Squamous Cell Carcinoma, Dysplasia
Peking University
Not applicable
33,948
Beijing
2012-01-01
Recruiting
Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
NCT04522687NSCLC, Esophageal Squamous Cell Carcinoma, Thymic Epithelial Tumor
Shanghai Cancer Hospital, China
Observational
500
Shanghai
2012-01-01
Rows per page Showing 1–93 of 93
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/esophageal-squamous-cell-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 93 of those studies listing the condition Esophageal Squamous Cell Carcinoma.

How many Esophageal Squamous Cell Carcinoma trials are recruiting in China?

60 of the 93 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 12 have not yet opened recruitment, 18 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Esophageal Squamous Cell Carcinoma), 93 studies
PhaseStudiesRecruitingShare
Phase 2473150.5%
Phase 313914%
Observational12812.9%
Not applicable838.6%
Phase 1636.5%
Phase 1/2545.4%
Phase 2/3222.2%

Most active sponsors

Lead sponsors with the most studies (Esophageal Squamous Cell Carcinoma)
Lead sponsorStudiesRecruiting
Fudan University73
Second Affiliated Hospital, Zhejiang University, School of Medicine53
Anhui Provincial Hospital44
Hebei Medical University Fourth Hospital41
Peking University41
Shanghai Chest Hospital43
Shanghai Zhongshan Hospital43
Tang-Du Hospital43
The First Affiliated Hospital with Nanjing Medical University43
Cancer Institute and Hospital, Chinese Academy of Medical Sciences31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.